Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:54 AM
Ignite Modification Date:
2025-12-25 @ 3:54 AM
NCT ID:
NCT06741202
Eligibility Criteria:
Inclusion Criteria:
* Eligible participants include any individual who identifies as a Veteran cisgender man with a history of MST, English-speaking, 18 years of age or older, and enrolled in the VAGLA. Participants must:
* comprehend and sign the informed consent form
* report a history of MST
* agree to complete research instruments
* Because we are looking for a range of impact among men MST survivors, participants will not be excluded based on psychiatric diagnosis
Exclusion Criteria:
* Per chart review conducted by the PI prior to screening and patient contact, Veterans will be excluded if they demonstrate:
* severe suicidal or homicidal ideation, defined using the Columbia Suicide Severity Rating Scale (C-SSRS) and behavioral flags per chart review
* severe and uncontrolled substance abuse (identified through current treatment of a substance use disorder in chart)
* illness that inhibits engagement in study procedures (e.g., inability to attend in-person visits)
* inability to self-consent to participate
* completion of CPT, PE, or the MMG 5 or fewer years ago
* concurrent enrollment in a trauma-focused intervention
* Through chart review, Veterans who dropped out of these treatments after 3 sessions will still be eligible as this is considered "early dropout."
* If immediate clinical attention is warranted, Veterans will receive immediate care via procedures outlined in the human subjects protection plan
Healthy Volunteers:
False
Sex:
MALE
Study:
NCT06741202
Study Brief:
Protocol Section:
NCT06741202